Dexelvucitabine is a failed experimental agent for the management of HIV infection. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.[medical citation needed]; On April 3, 2006, Pharmasset and Incyte, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme, lipase) in a phase II trial.

CAS：134379-77-4
中文别名：
英文别名：Reverset;Dexelvucitabine;DFC;YZ-817;2\',3\'-didehydro-2,3-dideoxy-5-fluorocytidine;D-D4FC;INCB-8721;DPC-817;
分子式：C9H10FN3O3
分子量：227.192
精确质量：227.071
Psa：90.37
Logp：-0.0083

UNII：KU8SPJ271W

密度：1.66g/cm3
沸点：394.9ºC at 760mmHg
闪点：192.6ºC
折射率：1.665
蒸汽压：7.15E-08mmHg at 25°C